A phase I/II, multi-center, open-label, repeat-dose study of forodesine hydrochloride infusion in patients with B-cell acute lymphoblastic leukemia with an option of extended use of forodesine hydrochloride

Trial Profile

A phase I/II, multi-center, open-label, repeat-dose study of forodesine hydrochloride infusion in patients with B-cell acute lymphoblastic leukemia with an option of extended use of forodesine hydrochloride

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2014

At a glance

  • Drugs Forodesine (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 17 Jan 2008 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 28 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top